675 related articles for article (PubMed ID: 26406377)
41. Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxyl-terminal domain kinases cdk9 and cdk7 at the viral transcriptosome.
Kapasi AJ; Spector DH
J Virol; 2008 Jan; 82(1):394-407. PubMed ID: 17942543
[TBL] [Abstract][Full Text] [Related]
42. Nanomaterial-Facilitated Cyclin-Dependent Kinase 7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction.
Huang CS; Xu QC; Dai C; Wang L; Tien YC; Li F; Su Q; Huang XT; Wu J; Zhao W; Yin XY
ACS Nano; 2021 Sep; 15(9):14744-14755. PubMed ID: 34405985
[TBL] [Abstract][Full Text] [Related]
43. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K
Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387
[TBL] [Abstract][Full Text] [Related]
44. Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma.
Zhang J; Liu S; Ye Q; Pan J
Mol Cancer; 2019 Sep; 18(1):140. PubMed ID: 31526394
[TBL] [Abstract][Full Text] [Related]
45. CDK7-dependent transcriptional addiction in bone and soft tissue sarcomas: Present and Future.
Yuan J; Li X; Yu S
Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188680. PubMed ID: 35051528
[TBL] [Abstract][Full Text] [Related]
46. The effect of miR-340 over-expression on cell-cycle-related genes in triple-negative breast cancer cells.
Mohammadi Yeganeh S; Vasei M; Tavakoli R; Kia V; Paryan M
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27229858
[TBL] [Abstract][Full Text] [Related]
47. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer.
Wei D; Wang H; Zeng Q; Wang W; Hao B; Feng X; Wang P; Song N; Kan W; Huang G; Zhou X; Tan M; Zhou Y; Huang R; Li J; Chen XH
J Med Chem; 2021 Oct; 64(19):14822-14847. PubMed ID: 34538051
[TBL] [Abstract][Full Text] [Related]
48. PML promotes metastasis of triple-negative breast cancer through transcriptional regulation of HIF1A target genes.
Ponente M; Campanini L; Cuttano R; Piunti A; Delledonne GA; Coltella N; Valsecchi R; Villa A; Cavallaro U; Pattini L; Doglioni C; Bernardi R
JCI Insight; 2017 Feb; 2(4):e87380. PubMed ID: 28239645
[TBL] [Abstract][Full Text] [Related]
49. Interaction with cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration.
Wang Y; Liu F; Mao F; Hang Q; Huang X; He S; Wang Y; Cheng C; Wang H; Xu G; Zhang T; Shen A
J Biol Chem; 2013 Mar; 288(13):9028-34. PubMed ID: 23393140
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
Quereda V; Bayle S; Vena F; Frydman SM; Monastyrskyi A; Roush WR; Duckett DR
Cancer Cell; 2019 Nov; 36(5):545-558.e7. PubMed ID: 31668947
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic targeting of transcriptional cyclin-dependent kinases.
Galbraith MD; Bender H; Espinosa JM
Transcription; 2019 Apr; 10(2):118-136. PubMed ID: 30409083
[TBL] [Abstract][Full Text] [Related]
52. CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.
Kim J; Cho YJ; Ryu JY; Hwang I; Han HD; Ahn HJ; Kim WY; Cho H; Chung JY; Hewitt SM; Kim JH; Kim BG; Bae DS; Choi CH; Lee JW
Gynecol Oncol; 2020 Jan; 156(1):211-221. PubMed ID: 31776040
[TBL] [Abstract][Full Text] [Related]
53. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
[TBL] [Abstract][Full Text] [Related]
54. Control of Expression of Key Cell Cycle Enzymes Drives Cell Line-Specific Functions of CDK7 in Human PDAC Cells.
Kolloch L; Kreinest T; Meisterernst M; Oeckinghaus A
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054996
[TBL] [Abstract][Full Text] [Related]
55. PDSS1-Mediated Activation of CAMK2A-STAT3 Signaling Promotes Metastasis in Triple-Negative Breast Cancer.
Yu TJ; Liu YY; Li XG; Lian B; Lu XX; Jin X; Shao ZM; Hu X; Di GH; Jiang YZ
Cancer Res; 2021 Nov; 81(21):5491-5505. PubMed ID: 34408002
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of CDK7-dependent transcriptional addiction is a potential therapeutic target in synovial sarcoma.
Li X; Dean DC; Yuan J; Temple TH; Trent JC; Rosenberg AE; Yu S; Hornicek FJ; Duan Z
Biomed Pharmacother; 2022 May; 149():112888. PubMed ID: 35367753
[TBL] [Abstract][Full Text] [Related]
57. Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcription.
Rimel JK; Poss ZC; Erickson B; Maas ZL; Ebmeier CC; Johnson JL; Decker TM; Yaron TM; Bradley MJ; Hamman KB; Hu S; Malojcic G; Marineau JJ; White PW; Brault M; Tao L; DeRoy P; Clavette C; Nayak S; Damon LJ; Kaltheuner IH; Bunch H; Cantley LC; Geyer M; Iwasa J; Dowell RD; Bentley DL; Old WM; Taatjes DJ
Genes Dev; 2020 Nov; 34(21-22):1452-1473. PubMed ID: 33060135
[TBL] [Abstract][Full Text] [Related]
58. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
Ali S; Heathcote DA; Kroll SH; Jogalekar AS; Scheiper B; Patel H; Brackow J; Siwicka A; Fuchter MJ; Periyasamy M; Tolhurst RS; Kanneganti SK; Snyder JP; Liotta DC; Aboagye EO; Barrett AG; Coombes RC
Cancer Res; 2009 Aug; 69(15):6208-15. PubMed ID: 19638587
[TBL] [Abstract][Full Text] [Related]
59. Structural basis for CDK7 activation by MAT1 and Cyclin H.
Peissert S; Schlosser A; Kendel R; Kuper J; Kisker C
Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26739-26748. PubMed ID: 33055219
[TBL] [Abstract][Full Text] [Related]
60. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer.
Wang BY; Liu QY; Cao J; Chen JW; Liu ZS
Drug Des Devel Ther; 2016; 10():1181-9. PubMed ID: 27042010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
